▲ Human lifespan evidence: no healthy-aging lifespan RCT — the randomized/prospective outcome evidence is in a rare telomere DISEASE population (telomeropathy with marrow failure), not healthy aging, and androgen adverse effects are significant

Two caveats govern every page on this site. (1) Telomere length is a contested aging biomarker — it is measured differently by different methods, varies between tissues, and "longer" is not straightforwardly "healthier"; changing a telomere-length or telomerase-activity number in a trial is not the same as slowing human aging. (2) Activating telomerase is not risk-free — telomerase is silenced in most somatic cells and reactivated in most cancers, so its activation raises an unresolved cancer-risk question. Tellingly, the only FDA-approved telomerase drug — imetelstat (RYTELO, 2024) — inhibits telomerase to treat cancer (lower-risk MDS), the opposite direction from the anti-aging "activation" narrative.

What it is

Class: Anabolic-androgenic steroid (telomere-disease treatment)

Also known as: danazol, attenuated androgen

Relationship to telomere biology: Danazol is an attenuated androgen. Androgens can upregulate telomerase (TERT) expression, which is the rationale for using danazol in inherited telomere-biology disorders (telomeropathies) that cause marrow failure. Its key human evidence is a clinical-outcome trial in a rare DISEASE population, not healthy aging.

Regulatory status

Danazol is an approved androgen (used historically for endometriosis and hereditary angioedema); its use in telomere disease is off-label/investigational. It is a prescription drug with significant androgenic and hepatic adverse effects. Not approved for any anti-aging indication.

Mechanism

Androgen-driven upregulation of telomerase reduced the rate of telomere attrition and improved blood counts in patients with telomeropathy and marrow failure (Townsley 2016, NEJM). This is disease treatment. See /telomerase-tert-terc.

Evidence — Human (prospective clinical trial — rare disease population)

Species / population	27 patients with telomere diseases (telomeropathy) and associated bone-marrow failure (Townsley 2016).
Exposure, route, schedule	Oral danazol 800 mg/day for up to 24 months.
Comparator / duration	Single-arm prospective trial with a pre-specified telomere-attrition endpoint (the trial was stopped early for efficacy).
Endpoint / numeric result	Attenuation or reversal of telomere attrition in ~92% of evaluable patients and hematologic responses (improved blood counts).
What it did NOT establish	This is treatment of a rare genetic DISEASE, not healthy aging. It says nothing about lifespan extension in healthy people, and androgen toxicity limits any general use.

Negative or null findings

Androgens including danazol carry hepatotoxicity, virilization, and other adverse effects — the benefit here is disease-specific and risk-laden.
A separate prospective trial of the androgen nandrolone in telomeropathies (Clé 2019) reported telomere elongation and clinical improvement, but is likewise a rare-disease result, not healthy aging.

Danazol (androgen)

What it is

Regulatory status

Mechanism

Evidence — Human (prospective clinical trial — rare disease population)

Negative or null findings

Studies on this page

Related mechanisms